Literature DB >> 9646035

p53 mutations in chondrosarcoma.

R M Terek1, J H Healey, P Garin-Chesa, S Mak, A Huvos, A P Albino.   

Abstract

Chondrosarcoma is a primary bone tumor that has several different grades and variants. We evaluated 48 chondrosarcomas for p53 overexpression and p53 mutations. p53 expression was evaluated with immunohistochemistry using monoclonal antibodies PAb421, PAb1801, and PAb240. p53 mutations were identified with single-strand conformational polymorphism (SSCP) and DNA sequencing in selected cases. Immunohistochemistry revealed nuclear staining with PAb421 and PAb1801 in the spindle cell portion of one dedifferentiated chondrosarcoma. SSCP analysis was abnormal only in the case with positive immunostaining and localized the mutation to exons 7 and 8. DNA sequence analysis identified a point mutation of G to C in codon 276, resulting in an amino acid substitution of proline for alanine. This point mutation has been reported previously in other tumors but not in chondrosarcoma. Assimilation of our results with previous studies suggests that p53 mutations are present in a minority of chondrosarcomas but when present, are in higher grade chondrosarcomas and their variants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9646035     DOI: 10.1097/00019606-199802000-00009

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  17 in total

Review 1.  Molecular pathology of chondroid neoplasms: part 2, malignant lesions.

Authors:  W C Bell; M J Klein; M J Pitt; G P Siegal
Journal:  Skeletal Radiol       Date:  2006-10-18       Impact factor: 2.199

2.  Dedifferentiated peripheral chondrosarcoma: a clinicopathologic, immunohistochemical, and molecular analysis of four cases.

Authors:  Alessandro Franchi; Gianna Baroni; Iacopo Sardi; Laura Giunti; Rodolfo Capanna; Domenico Campanacci
Journal:  Virchows Arch       Date:  2012-02-16       Impact factor: 4.064

3.  Characterization of a new human cell line (CH-3573) derived from a grade II chondrosarcoma with matrix production.

Authors:  Silvia Calabuig-Fariñas; Rosario Gil Benso; Karoly Szuhai; Isidro Machado; José Antonio López-Guerrero; Danielle de Jong; Amando Peydró; Teresa San Miguel; Lara Navarro; Antonio Pellín; Antonio Llombart-Bosch
Journal:  Pathol Oncol Res       Date:  2012-02-15       Impact factor: 3.201

4.  Treatment of Bone Tumors.

Authors:  Rajiv Rajani; C Parker Gibbs
Journal:  Surg Pathol Clin       Date:  2012-03

Review 5.  Review of therapeutic strategies for osteosarcoma, chondrosarcoma, and Ewing's sarcoma.

Authors:  Xing Dai; Wei Ma; Xijing He; Rajiv Kumar Jha
Journal:  Med Sci Monit       Date:  2011-08

6.  Chondrosarcoma: with updates on molecular genetics.

Authors:  Mi-Jung Kim; Kyung-Ja Cho; Alberto G Ayala; Jae Y Ro
Journal:  Sarcoma       Date:  2011-02-15

7.  Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.

Authors:  J G van Oosterwijk; M A J H van Ruler; I H Briaire-de Bruijn; B Herpers; H Gelderblom; B van de Water; J V M G Bovée
Journal:  Br J Cancer       Date:  2013-08-06       Impact factor: 7.640

8.  Chondrosarcoma and peroxisome proliferator-activated receptor.

Authors:  K Nishida; T Kunisada; Z N Shen; Y Kadota; K Hashizume; T Ozaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  Chondrosarcoma of the spine: a rare case with unusual presentation.

Authors:  John Panelos; Spyridon Voulgaris; Evangelos Michos; Michael Doukas; Konstantinos Charalabopoulos; Anna Batistatou
Journal:  Diagn Pathol       Date:  2006-10-30       Impact factor: 2.644

10.  The molecular pathogenesis of dedifferentiated chondrosarcoma.

Authors:  Akio Sakamoto
Journal:  Indian J Orthop       Date:  2014-05       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.